The Diabetes Injection Pens Market is expected to witness a growth rate of ~7% by 2028. The key factors driving the market are the rising prevalence of diabetes, the growing preference for pens over ...

Find patient medical information for Insulin Glargine on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

The global Insulin Delivery Device Market, valued at US$32.6 billion in 2024 stood at US$35.3 billion in 2025 and is ...

The cure for diabetes is a life free from daily insulin injections. Based on that criterion, ten out of 12 people (83%) in a ...

Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba®).

Insulin pen devices have been shown to provide more ... in South Africa faced a significant setback for people with diabetes. ... forcing patients to revert to using syringes for their injections.

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...